Evidence map›Paper›PMID 39795120›Full record

ArticleMolecules (Basel, Switzerland)2024

Structure-Activity Relationship Studies of Tetracyclic Pyrrolocarbazoles Inhibiting Heterotetrameric Protein Kinase CK2.

Lukas Kröger, Sebastian Borgert, Miriam Lauwers, Michaela Steinkrüger, Joachim Jose, Markus Pietsch, Bernhard Wünsch

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lukas KrögerInstitut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany.
Sebastian BorgertInstitut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany.ORCID 0000-0002-7140-1907
Miriam LauwersInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, D-50931 Cologne, Germany.ORCID 0000-0001-9619-8450
Michaela SteinkrügerInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, D-50931 Cologne, Germany.
Joachim JoseInstitut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany.ORCID 0000-0002-0666-2676
Markus PietschInstitutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, D-50931 Cologne, Germany.ORCID 0000-0002-8110-2265
Bernhard WünschInstitut für Pharmazeutische und Medizinische Chemie, Universität Münster, Corrensstraße 48, D-48149 Münster, Germany.ORCID 0000-0002-9030-8417

Funding

Deutsche Forschungsgemeinschaft WU 176
6 · The paper itself

Abstract

The serine/threonine kinase CK2 (formerly known as casein kinase II) plays a crucial role in various CNS disorders and is highly expressed in various types of cancer. Therefore, inhibiting this key kinase could be promising for the treatment of these diseases. The CK2 holoenzyme is formed by the recruitment of two catalytically active CK2α and/or CK2α' subunits by a regulatory CK2β dimer. Starting with the lead furocarbazole W16 (

Indexed as

CarbazolesCasein Kinase IIProtein Kinase InhibitorsHumansMolecular StructureProtein BindingProtein MultimerizationStructure-Activity RelationshipCarbazolesCasein Kinase IIProtein Kinase Inhibitorscapillary electrophoresisCK2enzyme inhibitionheterotetrameric enzymeLevy reactionmicroscale thermophoresisprotein kinaseprotein–protein interactionstereochemistrystructure–activity relationshipssurface enlargement

Identifiers

PMID39795120
PMCPMC11722180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.